C4X Discovery signs potential $402mln deal | News Direct

C4X Discovery signs potential $402mln deal

C4X Discovery Holdings PLC
Digital Asset Direct by C4X Discovery Holdings PLC
Download PDF Download multimedia

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | November 28, 2022 09:30 AM Eastern Standard Time

C4X Discovery Holdings CEO Clive Dix and chief business officer Bhavna Hunjan speak to Proactive after announcing an exclusive global licence deal with AstraZeneca to develop and commercialise C4X Discovery's NRF2 activator programme. The deal may ultimately be worth up to $402mln to the drug discovery company, and is structured to provide C4X Discovery with another steady stream of income.

 

Contact Details

 

Proactive

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com

DOWNLOAD

project media

Tags

HealthPharma & BiotechDrug DiscoveryAstraZeneca
News Direct Logo
Follow us on Facebook Follow us on LinkedIn
Get the latest from News Direct
Contact Us Pricing
Why News Direct
About us Features News Hub
Resources
Terms of Use Privacy Policy
newsdirect.com © 2025 News Direct Corp. All rights reserved. News Direct is a registered trademark.